vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and GigaCloud Technology Inc (GCT). Click either name above to swap in a different company.

GigaCloud Technology Inc is the larger business by last-quarter revenue ($332.6M vs $156.4M, roughly 2.1× BIOCRYST PHARMACEUTICALS INC). On growth, GigaCloud Technology Inc posted the faster year-over-year revenue change (9.7% vs 7.5%). Over the past eight quarters, GigaCloud Technology Inc's revenue compounded faster (36.6% CAGR vs 19.6%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

GigaCloud Technology Inc. is an American e-commerce company that helps retailers buy and sell big and bulky, non-standardized items such as furniture, appliances, and fitness equipment. They own a business-to-business online marketplace and act as a middleman by handling sales, logistics and also delivery to end customers. GigaCloud is headquartered in El Monte, California, and is listed on the Nasdaq stock exchange since August 2022.

BCRX vs GCT — Head-to-Head

Bigger by revenue
GCT
GCT
2.1× larger
GCT
$332.6M
$156.4M
BCRX
Growing faster (revenue YoY)
GCT
GCT
+2.2% gap
GCT
9.7%
7.5%
BCRX
Faster 2-yr revenue CAGR
GCT
GCT
Annualised
GCT
36.6%
19.6%
BCRX

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
BCRX
BCRX
GCT
GCT
Revenue
$156.4M
$332.6M
Net Profit
$37.2M
Gross Margin
23.2%
Operating Margin
13.6%
12.2%
Net Margin
11.2%
Revenue YoY
7.5%
9.7%
Net Profit YoY
-8.6%
EPS (diluted)
$0.00
$0.99

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
GCT
GCT
Q1 26
$156.4M
Q4 25
$406.6M
Q3 25
$159.4M
$332.6M
Q2 25
$163.4M
$322.6M
Q1 25
$145.5M
$271.9M
Q4 24
$131.5M
$295.8M
Q3 24
$117.1M
$303.3M
Q2 24
$109.3M
$310.9M
Net Profit
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
$245.8M
Q3 25
$12.9M
$37.2M
Q2 25
$5.1M
$34.6M
Q1 25
$32.0K
$27.1M
Q4 24
$-26.8M
$31.0M
Q3 24
$-14.0M
$40.7M
Q2 24
$-12.7M
$27.0M
Gross Margin
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
97.7%
Q3 25
98.6%
23.2%
Q2 25
98.3%
23.9%
Q1 25
96.9%
23.4%
Q4 24
95.4%
22.0%
Q3 24
97.3%
25.5%
Q2 24
98.4%
24.6%
Operating Margin
BCRX
BCRX
GCT
GCT
Q1 26
13.6%
Q4 25
64.0%
Q3 25
18.6%
12.2%
Q2 25
18.2%
11.1%
Q1 25
14.6%
10.4%
Q4 24
-3.4%
9.3%
Q3 24
6.6%
13.4%
Q2 24
8.0%
8.8%
Net Margin
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
60.5%
Q3 25
8.1%
11.2%
Q2 25
3.1%
10.7%
Q1 25
0.0%
10.0%
Q4 24
-20.4%
10.5%
Q3 24
-12.0%
13.4%
Q2 24
-11.6%
8.7%
EPS (diluted)
BCRX
BCRX
GCT
GCT
Q1 26
$0.00
Q4 25
$1.13
Q3 25
$0.06
$0.99
Q2 25
$0.02
$0.91
Q1 25
$0.00
$0.68
Q4 24
$-0.13
$0.76
Q3 24
$-0.07
$0.98
Q2 24
$-0.06
$0.65

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
GCT
GCT
Cash + ST InvestmentsLiquidity on hand
$259.0M
$365.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$457.3M
Total Assets
$465.1M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
GCT
GCT
Q1 26
$259.0M
Q4 25
$274.7M
Q3 25
$212.9M
$365.9M
Q2 25
$260.0M
$303.0M
Q1 25
$295.1M
$286.8M
Q4 24
$320.9M
$302.4M
Q3 24
$96.8M
$259.8M
Q2 24
$78.4M
$207.8M
Stockholders' Equity
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
$-119.2M
Q3 25
$-387.9M
$457.3M
Q2 25
$-421.6M
$431.4M
Q1 25
$-451.9M
$412.9M
Q4 24
$-475.9M
$405.2M
Q3 24
$-468.6M
$400.4M
Q2 24
$-475.6M
$358.4M
Total Assets
BCRX
BCRX
GCT
GCT
Q1 26
$465.1M
Q4 25
$514.2M
Q3 25
$446.4M
$1.1B
Q2 25
$457.2M
$1.1B
Q1 25
$480.0M
$1.1B
Q4 24
$490.4M
$1.1B
Q3 24
$491.3M
$1.1B
Q2 24
$472.4M
$1.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
GCT
GCT
Operating Cash FlowLast quarter
$78.3M
Free Cash FlowOCF − Capex
$77.1M
FCF MarginFCF / Revenue
23.2%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
2.10×
TTM Free Cash FlowTrailing 4 quarters
$188.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
$292.0M
Q3 25
$41.6M
$78.3M
Q2 25
$41.3M
$38.6M
Q1 25
$-27.5M
$9.4M
Q4 24
$-5.2M
$68.4M
Q3 24
$8.2M
$55.2M
Q2 24
$-1.4M
$19.1M
Free Cash Flow
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
$291.2M
Q3 25
$40.3M
$77.1M
Q2 25
$41.1M
$37.0M
Q1 25
$-27.7M
$7.0M
Q4 24
$-5.9M
$66.9M
Q3 24
$8.2M
$51.4M
Q2 24
$-1.5M
$12.9M
FCF Margin
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
71.6%
Q3 25
25.3%
23.2%
Q2 25
25.2%
11.5%
Q1 25
-19.0%
2.6%
Q4 24
-4.5%
22.6%
Q3 24
7.0%
16.9%
Q2 24
-1.4%
4.2%
Capex Intensity
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
0.2%
Q3 25
0.8%
0.4%
Q2 25
0.1%
0.5%
Q1 25
0.1%
0.9%
Q4 24
0.5%
0.5%
Q3 24
0.1%
1.3%
Q2 24
0.1%
2.0%
Cash Conversion
BCRX
BCRX
GCT
GCT
Q1 26
Q4 25
1.19×
Q3 25
3.23×
2.10×
Q2 25
8.12×
1.12×
Q1 25
-859.91×
0.35×
Q4 24
2.21×
Q3 24
1.36×
Q2 24
0.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

GCT
GCT

Services$108.4M33%
Transferred Over Time$89.8M27%
Product Sales To B$50.1M15%
Last Mile Delivery Service$49.2M15%
Warehousing Service$14.2M4%
Ocean Transportation Service$9.0M3%
Platform Commission$4.9M1%
Drayage Service$3.2M1%

Related Comparisons